Vanda Pharmaceuticals

#CNS #Mental Health #Rare Disease #Dermatology

Washington, DC-based biopharmaceutical company developing and commercializing therapies for central nervous system disorders, dermatologic conditions, and rare diseases, with three FDA-approved products on market.

Company Info

Sector:Specialty Pharma

Headquarters:Washington, DC, USA

Founded:2002

Website:www.vandapharma.com/

Upcoming Milestones & Key Dates

2026-07-08

regulatory

FDA Rare Pediatric Disease Designation announcement

2026-Q4

regulatory

Bysanti NDA PDUFA action date expected

Clinical Development Pipeline

Bysanti (milsaperidone)

Target: D2 antagonist / 5-HT antagonist

Acute bipolar I disorder / schizophrenia

Preclinical

Phase 1

Phase 2

Phase 3

Approved

VCA-894A

Target: Histamine H1 antagonist

Niemann-Pick disease type C

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Tradipitant

Target: NK-1 antagonist

Atopic dermatitis / gastroparesis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Vanda shifts into high gear with Schumacher IndyCar sponsorship ↗

Vanda launches a motorsport marketing push with a Schumacher IndyCar sponsorship.

Clinical Regulatory•Jul 7, 2026•PR Newswire

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S ↗

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S (reported by PR Newswire)

Leadership Team

Mihael H. Polymeropoulos

President and Chief Executive Officer

Kevin Moran

Chief Financial Officer

Careers & Job Openings

See all open roles

All departments

See company careers site

Apply Now →